Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Consensus Rating of “Reduce” from Brokerages

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have been assigned an average recommendation of “Reduce” from the six brokerages that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $30.00.

Several analysts have recently commented on FMS shares. Zacks Research cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 4th. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Wall Street Zen lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently modified their holdings of the company. Pzena Investment Management LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 0.6% in the first quarter. Pzena Investment Management LLC now owns 15,377,090 shares of the company’s stock valued at $382,890,000 after purchasing an additional 94,065 shares in the last quarter. Todd Asset Management LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 5.2% during the 3rd quarter. Todd Asset Management LLC now owns 1,303,424 shares of the company’s stock valued at $34,319,000 after buying an additional 64,311 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 50.0% during the 1st quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock valued at $26,982,000 after buying an additional 361,364 shares during the last quarter. Hennessy Advisors Inc. bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at approximately $11,479,000. Finally, Northern Trust Corp increased its holdings in Fresenius Medical Care AG & Co. KGaA by 5.0% in the first quarter. Northern Trust Corp now owns 380,251 shares of the company’s stock worth $9,468,000 after buying an additional 18,061 shares during the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Fresenius Medical Care AG & Co. KGaA stock opened at $24.01 on Monday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $21.06 and a fifty-two week high of $30.46. The firm’s 50 day simple moving average is $25.98 and its 200-day simple moving average is $26.60. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.44 and a quick ratio of 1.08. The company has a market cap of $14.09 billion, a P/E ratio of 19.68, a price-to-earnings-growth ratio of 0.64 and a beta of 0.90.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The firm had revenue of $5.63 billion during the quarter, compared to analyst estimates of $4.72 billion. As a group, equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.